In the evolving landscape of global pharmaceutical markets, China‘s introduction of the Commercial Health Insurance Innovative Drug List represents a pivotal policy maneuver aimed at bridging the gap between rapid innovation in high-cost therapies and equitable access for its 1.4 billion population. This initiative, spearheaded by the National Healthcare Security Administration (NHSA), addresses the core … Leggi tutto China’s Commercial Health Insurance Innovative Drug List: Expanding Access to Advanced Therapies in 2025